Trials / Completed
CompletedNCT03433027
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Benitec Biopharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BB-401 | BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks |
Timeline
- Start date
- 2018-03-15
- Primary completion
- 2018-12-12
- Completion
- 2020-04-06
- First posted
- 2018-02-14
- Last updated
- 2020-04-15
Locations
6 sites across 2 countries: Australia, Russia
Source: ClinicalTrials.gov record NCT03433027. Inclusion in this directory is not an endorsement.